Concepedia

Benjamin Y. Kong

BY

16

Publications

2.6K

Citations

15

H-Index

2002

Active since

Affiliations

The University of Sydney(Current)

Melanoma Institute Australia

Royal North Shore Hospital

Westmead Hospital

Macquarie University

Benjamin Y. Kong is an author at The University of Sydney specializing in medicine, immunotherapy, and pathology.

ORCID

Top concepts

Publications per year

2002–2023

16

Publications

16

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo et al. · Journal of Clinical Oncology · 2016 · 1.1K citations · Full text

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade et al. · Journal of the American Academy of Dermatology · 2016 · 302 citations · Full text

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long, Victoria Atkinson, Jonathan Cebon et al. · The Lancet Oncology · 2017 · 246 citations · Full text

, , +9

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma

Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott et al. · Clinical Cancer Research · 2017 · 243 citations · Full text

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

Elizabeth Liniker, Alexander M. Menzies, Benjamin Y. Kong et al. · OncoImmunology · 2016 · 150 citations · Full text

Rows per page

1–5 of 16